Avosentan (BioDeep_00000176331)
human metabolite blood metabolite
代谢物信息卡片
5-Methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide
化学式: C23H21N5O5S (479.12633360000007)
中文名称: 阿伏生
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC=NC=C3)OC)OC4=CC=CC=C4OC
InChI: InChI=1S/C23H21N5O5S/c1-15-8-9-19(25-14-15)34(29,30)28-22-20(33-18-7-5-4-6-17(18)31-2)23(32-3)27-21(26-22)16-10-12-24-13-11-16/h4-14H,1-3H3,(H,26,27,28)
描述信息
C28313 - Endothelin Receptor Antagonist
Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist. IC50 value: Target: ETA receptor
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- PubChem: 9912992
- HMDB: HMDB0248748
- ChEMBL: CHEMBL3989834
- chemspider: 8088643
- CAS: 290815-26-8
- medchemexpress: HY-15195
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Y Zhou, J Chi, Y Huang, B Dong, W Lv, Y G Wang. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Diabetic medicine : a journal of the British Diabetic Association.
2021 01; 38(1):e14411. doi:
10.1111/dme.14411. [PMID: 33000477] - Sergio Stefoni, Giuseppe Cianciolo, Olga Baraldi, Mario Iorio, Maria Laura Angelini. Emerging drugs for chronic kidney disease.
Expert opinion on emerging drugs.
2014 Jun; 19(2):183-99. doi:
10.1517/14728214.2014.900044. [PMID: 24836744] - Jamo Hoekman, Hiddo J Lambers Heerspink, Giancarlo Viberti, Damien Green, Johannes F E Mann, Dick de Zeeuw. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.
Clinical journal of the American Society of Nephrology : CJASN.
2014 Mar; 9(3):490-8. doi:
10.2215/cjn.07040713. [PMID: 24408122] - Ovidiu C Baltatu, Christian E Zaugg, Christoph Schumacher, Pat Louie, Luciana A Campos, Michael Bader. Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.
Pharmacological research.
2014 Feb; 80(?):9-13. doi:
10.1016/j.phrs.2013.12.003. [PMID: 24368192] - Donald E Kohan, David M Pollock. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
British journal of clinical pharmacology.
2013 Oct; 76(4):573-9. doi:
10.1111/bcp.12064. [PMID: 23228194] - B Fernández Fernández, U Elewa, M D Sánchez-Niño, J E Rojas-Rivera, C Martin-Cleary, J Egido, A Ortiz. 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.
Minerva medica.
2012 Aug; 103(4):219-34. doi:
. [PMID: 22805616] - Ovidiu Constantin Baltatu, Radu Iliescu, Christian E Zaugg, Jane F Reckelhoff, Pat Louie, Christoph Schumacher, Luciana Aparecida Campos. Antidiuretic effects of the endothelin receptor antagonist avosentan.
Frontiers in physiology.
2012; 3(?):103. doi:
10.3389/fphys.2012.00103. [PMID: 22529820] - Ton J Rabelink, Donald E Kohan. Endothelin receptor blockade in patients with diabetic nephropathy.
Contributions to nephrology.
2011; 172(?):235-242. doi:
10.1159/000328703. [PMID: 21894003] - Matthias Barton. Endothelin antagonism and reversal of proteinuric renal disease in humans.
Contributions to nephrology.
2011; 172(?):210-222. doi:
10.1159/000328702. [PMID: 21894001] - Phyllis Chew, Derek Y C Yuen, Nada Stefanovic, Josefa Pete, Melinda T Coughlan, Karin A Jandeleit-Dahm, Merlin C Thomas, Franklin Rosenfeldt, Mark E Cooper, Judy B de Haan. Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.
Diabetes.
2010 Dec; 59(12):3198-207. doi:
10.2337/db10-0195. [PMID: 20823099] - Faruk Turgut, Warren Kline Bolton. Potential new therapeutic agents for diabetic kidney disease.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2010 May; 55(5):928-40. doi:
10.1053/j.ajkd.2009.11.021. [PMID: 20138415] - Johannes F E Mann, Damian Green, Kenneth Jamerson, Luis M Ruilope, Susan J Kuranoff, Thomas Littke, Giancarlo Viberti. Avosentan for overt diabetic nephropathy.
Journal of the American Society of Nephrology : JASN.
2010 Mar; 21(3):527-35. doi:
10.1681/asn.2009060593. [PMID: 20167702] - A M D Watson, J Li, C Schumacher, M de Gasparo, B Feng, M C Thomas, T J Allen, M E Cooper, K A M Jandeleit-Dahm. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
Diabetologia.
2010 Jan; 53(1):192-203. doi:
10.1007/s00125-009-1540-3. [PMID: 19862499] - Elena Gagliardini, Daniela Corna, Carla Zoja, Fabio Sangalli, Fabiola Carrara, Matteo Rossi, Sara Conti, Daniela Rottoli, Lorena Longaretti, Andrea Remuzzi, Giuseppe Remuzzi, Ariela Benigni. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
American journal of physiology. Renal physiology.
2009 Nov; 297(5):F1448-56. doi:
10.1152/ajprenal.00340.2009. [PMID: 19675181] - W Dieterle, T Hengelage. Absolute bioavailability and pharmacokinetics of avosentan in man.
International journal of clinical pharmacology and therapeutics.
2009 Sep; 47(9):587-94. doi:
10.5414/cpp47587. [PMID: 19761718] - J Smolander, B Vogt, M Maillard, C Zweiacker, T Littke, T Hengelage, M Burnier. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.
Clinical pharmacology and therapeutics.
2009 Jun; 85(6):628-34. doi:
10.1038/clpt.2009.15. [PMID: 19279566] - René R Wenzel, Thomas Littke, Susan Kuranoff, Christiane Jürgens, Heike Bruck, Eberhard Ritz, Thomas Philipp, Anna Mitchell. Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
Journal of the American Society of Nephrology : JASN.
2009 Mar; 20(3):655-64. doi:
10.1681/asn.2008050482. [PMID: 19144760] - W Dieterle, T Hengelage. Influence of food intake on the pharmacokinetics of avosentan in man.
International journal of clinical pharmacology and therapeutics.
2008 Sep; 46(9):453-8. doi:
10.5414/cpp46453. [PMID: 18793575] - W Dieterle, J Mann. Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
International journal of clinical pharmacology and therapeutics.
2006 Dec; 44(12):668-74. doi:
10.5414/cpp44668. [PMID: 17190377] - W Dieterle, J Mann. Pharmacokinetic interaction between ketoconazole and SPP301 in healthy volunteers.
International journal of clinical pharmacology and therapeutics.
2006 Jul; 44(7):326-30. doi:
10.5414/cpp44326. [PMID: 16961161] - W Dieterle, J Mann, K Kutz. Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
International journal of clinical pharmacology and therapeutics.
2005 Apr; 43(4):178-86. doi:
10.5414/cpp43178. [PMID: 15966464] - Walter Dieterle, Jessica Mann, Klaus Kutz. Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects.
Journal of clinical pharmacology.
2004 Jan; 44(1):59-66. doi:
10.1177/0091270003261047. [PMID: 14681342]